XHXinyu Huang

Xinyu Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinyu Huang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Xu Zhang

    Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China

    3 shared publications
  • Daoming Bai

    Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China

    2 shared publications
  • Mengyuan Liu

    Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China

    2 shared publications
  • Rui Yang

    Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China

    2 shared publications
  • Zhiqiang Zhang

    Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China

    2 shared publications
  • Chunhong Yu

    Department of Hepatobiliary Medicine Fuzong Clinical Medical College of Fujian Medical University Fuzhou China

    1 shared publication

Latest Publications

  • The Nasal Microbiome in Inflammation and Disease: Bridging Mechanisms to Therapeutics

    by Xu Zhang, Chunhong Yu, Zhiqiang Zhang, Mengyuan Liu, Xinyu Huang, Daoming Bai, Rui Yang, Peng Wang, Chunping Yang

    The nasal microbiome, an integral component of the upper respiratory tract's microecological system, plays a pivotal role in inflammatory diseases such as allergic rhinitis and chronic sinusitis, which affect a substantial population and markedly reduce quality of life. A healthy nasal flora and its metabolites are crucial for maintaining immune homeostasis and mucosal barrier integrity. This review comprehensively discusses the pathological mechanisms, immune interactions, and clinical intervention strategies involving the nasal microbiota in nasal inflammation. It has been shown that dysbiosis of the nasal flora disrupts immune function and compromises the epithelial barrier, thereby initiating and exacerbating a vicious cycle of inflammation. Furthermore, the formation of bacterial biofilms and the emergence of drug resistance contribute to persistent and recurrent symptoms. Regarding treatment, while antibiotics may offer short‐term efficacy, they risk aggravating the microbial imbalance. In contrast, therapies including probiotics, novel immunomodulators, and traditional Chinese medicine demonstrate significant therapeutic potential by restoring microbial balance and modulating immune responses. This review synthesizes current research to provide new perspectives for understanding host–microbiome interactions and to guide future clinical treatments and drug development.


  • Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation

    by Xu Zhang, Zhiqiang Zhang, Mengyuan Liu, Xinyu Huang, Daoming Bai, Rui Yang, Chunping Yang

  • Open Access

    Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence

    by Xinyu Huang, Xu Zhang, Zhiqiang Zhang, Mengyuan Liu, Daoming Bai, Rui Yang, Chunping Yang

    Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.